<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Forodesine</id>
	<title>Forodesine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Forodesine"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Forodesine&amp;action=history"/>
	<updated>2026-05-11T04:25:22Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Forodesine&amp;diff=5368269&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Forodesine&amp;diff=5368269&amp;oldid=prev"/>
		<updated>2024-03-06T03:42:21Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Forodesine.png|thumb|{{PAGENAME}}]]&amp;lt;br&amp;gt;&amp;#039;&amp;#039;&amp;#039;Forodesine&amp;#039;&amp;#039;&amp;#039; is a [[transition state analog]] inhibitor that targets [[purine nucleoside phosphorylase]], an enzyme involved in the [[purine salvage pathway]]. It is currently under investigation for its potential use in the treatment of [[cutaneous T-cell lymphoma]] (CTCL) and [[B-cell acute lymphoblastic leukemia]] (B-ALL).&lt;br /&gt;
&lt;br /&gt;
== Mechanism of Action ==&lt;br /&gt;
&lt;br /&gt;
Forodesine inhibits the enzyme [[purine nucleoside phosphorylase]] (PNP), which plays a crucial role in the [[purine salvage pathway]]. This pathway is responsible for the recycling of purines in cells. By inhibiting PNP, forodesine disrupts the balance of purines in the cell, leading to an accumulation of [[deoxyguanosine triphosphate]] (dGTP) in [[lymphocytes]]. This accumulation triggers [[apoptosis]], or programmed cell death, in these cells.&lt;br /&gt;
&lt;br /&gt;
== Clinical Trials ==&lt;br /&gt;
&lt;br /&gt;
Forodesine has been investigated in several [[clinical trials]] for its potential use in treating various forms of [[cancer]]. In particular, it has shown promise in the treatment of [[cutaneous T-cell lymphoma]] (CTCL) and [[B-cell acute lymphoblastic leukemia]] (B-ALL). &lt;br /&gt;
&lt;br /&gt;
In a Phase I/II trial for patients with refractory CTCL, forodesine demonstrated significant clinical activity. A Phase II trial for patients with relapsed or refractory B-ALL also showed promising results, with a significant number of patients achieving complete remission.&lt;br /&gt;
&lt;br /&gt;
== Side Effects ==&lt;br /&gt;
&lt;br /&gt;
As with any drug, forodesine may cause side effects. The most common side effects reported in clinical trials include [[fatigue]], [[nausea]], and [[rash]]. Less common side effects include [[anemia]], [[neutropenia]], and [[thrombocytopenia]]. &lt;br /&gt;
&lt;br /&gt;
== Future Directions ==&lt;br /&gt;
&lt;br /&gt;
Further research is needed to fully understand the potential of forodesine in cancer treatment. Ongoing and future clinical trials will continue to evaluate the drug&amp;#039;s efficacy and safety profile in different patient populations and in combination with other therapies.&lt;br /&gt;
&lt;br /&gt;
[[Category:Drugs]]&lt;br /&gt;
[[Category:Cancer treatments]]&lt;br /&gt;
[[Category:Chemotherapy]]&lt;br /&gt;
[[Category:Experimental medical treatments]]&lt;br /&gt;
{{Chem-drug-stub}}&lt;br /&gt;
{{Cancer-stub}}&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>